Related Experiment Video

Updated: Mar 19, 2026

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.3K

Novel STAT 3 inhibitors for treating gastric cancer

Catherine Cafferkey1, Ian Chau1

  • 1a Gastrointestinal and lymphoma trials unit , Royal Marsden Hospital , London , United Kingdom.

Expert Opinion on Investigational Drugs
|June 21, 2016
PubMed
Abstract

Insights

Signal transducer and activator of transcription 3 (STAT3) inhibitors show promise for advanced gastric cancer, a disease with poor prognosis. Early trials suggest STAT3 plays a key role in tumor growth and metastasis, making it a potential therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Advanced gastric cancer presents a significant clinical challenge with a poor median survival of approximately 12 months.
  • There is an unmet need for novel therapeutic strategies to improve outcomes in advanced gastric cancer.
  • Signal transducer and activator of transcription 3 (STAT3) inhibitors are emerging as a promising class of drugs for various cancers, including gastric cancer.

Purpose of the Study:

  • To review the role of STAT3 in the pathogenesis of gastric cancer.
  • To explore the current landscape of early-phase clinical trials investigating STAT3 inhibitors in gastric cancer patients.
  • To discuss the preclinical and clinical data supporting the investigation of STAT3 inhibition in gastric cancer.

Main Methods:

  • Literature search of PubMed, clinicaltrials.gov, and ASCO abstracts for studies on STAT3 inhibitors.
  • Focus on trials specifically recruiting patients with gastric cancer.
  • Review of preclinical data and early clinical trial findings related to STAT3 inhibition.

Main Results:

  • Activated STAT3 is associated with poorer survival outcomes in gastric cancer patients.
  • STAT3 signaling is critical for regulating tumor growth and the development of metastases.
  • Early clinical trials indicate that STAT3 inhibitors are a potential therapeutic option for gastric cancer.

Conclusions:

  • STAT3 plays a crucial role in gastric cancer progression and is linked to poor prognosis.
  • STAT3 inhibitors represent a promising therapeutic avenue for advanced gastric cancer.
  • While early-phase trials are ongoing, with one agent in Phase III, further research is needed to establish the efficacy of STAT3 inhibitors.
Keywords:
Gastric cancerSTAT3STAT3 inhibitor

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.6K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
777
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
1.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
723
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K